GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guizhou Sanli Pharmaceutical Co Ltd (SHSE:603439) » Definitions » 3-Year Revenue Growth Rate

Guizhounli Pharmaceutical Co (SHSE:603439) 3-Year Revenue Growth Rate : 35.10% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Guizhounli Pharmaceutical Co 3-Year Revenue Growth Rate?

Guizhounli Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was ¥1.05.

During the past 12 months, Guizhounli Pharmaceutical Co's average Revenue per Share Growth Rate was 23.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 35.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of Guizhounli Pharmaceutical Co was 35.10% per year. The lowest was -2.70% per year. And the median was 11.70% per year.


Competitive Comparison of Guizhounli Pharmaceutical Co's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Guizhounli Pharmaceutical Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guizhounli Pharmaceutical Co's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Guizhounli Pharmaceutical Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Guizhounli Pharmaceutical Co's 3-Year Revenue Growth Rate falls into.



Guizhounli Pharmaceutical Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Guizhounli Pharmaceutical Co  (SHSE:603439) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Guizhounli Pharmaceutical Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Guizhounli Pharmaceutical Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Guizhounli Pharmaceutical Co (SHSE:603439) Business Description

Traded in Other Exchanges
N/A
Address
Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.

Guizhounli Pharmaceutical Co (SHSE:603439) Headlines

No Headlines